Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$6.65 - $10.04 $96,338 - $145,449
-14,487 Closed
0 $0
Q1 2021

May 06, 2021

BUY
$9.1 - $19.57 $131,831 - $283,510
14,487 New
14,487 $134,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $195M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Blueshift Asset Management, LLC Portfolio

Follow Blueshift Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Blueshift Asset Management, LLC with notifications on news.